3-乙基异硫氰酸苯酯 | 19241-20-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-乙基异硫氰酸苯酯
• 英文名称: 1-isothiocyanato-3-ethylbenzene
• 英文别名: 3-ethylphenyl isothiocyanate；3-phenylethyl isothiocyanate；3-ethylphenylisothiocyanate；m-Ethylphenyl-isothiocyanat；3-Ethylphenylisothiocyanat；1-ethyl-3-isothiocyanatobenzene
• CAS: 19241-20-4
• 化学式: C₉H₉NS
• mdl: MFCD00041084
• 分子量: 163.243
• InChiKey: FRMFJQIVPNSSPX-UHFFFAOYSA-N

物化性质

• 沸点：
  116 °C
• 密度：
  1.07

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  KEEP COLD, LACHRYMATOR, TOXIC
• 危险品标志：
  T
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 2810
• 海关编码：
  2930909090
• 安全说明：
  S26,S36/37/39
• 储存条件：
  请保持冷藏。

反应信息

• 作为反应物：
  描述：

  3-乙基异硫氰酸苯酯 在 sodium dithionite 、 氨 、 sodium ethanolate 、 溶剂黄146 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 9.25h， 生成 5,6-diamino-1-(3-ethylphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one
  参考文献：
  名称：

  WO2007/120097

  摘要：

  公开号：
• 作为产物：
  描述：

  二甲氨基硫代甲酰氯 、 3-乙基苯胺 以 甲苯 为溶剂， 反应 5.0h， 生成 3-乙基异硫氰酸苯酯
  参考文献：
  名称：

  Design, synthesis, biological activities, and dynamic simulation study of novel thiourea derivatives with gibberellin activity towards Arabidopsis thaliana

  摘要：

  Computer-aided drug design has advanced by leaps and bounds, and has been widely used in various fields, and especially in the field of drug discovery. Although the crystal structure of the gibberellin (GA) receptor GID1A had been reported in previous studies, there is still a lack of designs of gibberellin functional analogue based GID1A. In the present study, a series of 30 thiourea derivatives were designed, synthesized and biologically assayed. The results suggested that the synthetic compounds had good GA-like activities. Furthermore, the structure-activity relationship of the synthetic compounds was discussed, and the dynamic simulation and docking study revealed the binding properties of the GID1A receptor and compounds Y1, Y11, and Y21.

  DOI：

  10.1016/j.bmc.2019.06.032

文献信息

• Substituted benzimidazoles and methods of preparation
  申请人：Dimitroff Martin

  公开号：US20070049622A1

  公开（公告）日：2007-03-01

  Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R 1 , R 2 , R 3 , R 4 , a, b, and c are defined herein

  提供了制备新的取代苯并咪唑化合物的方法，其化学式为（I），用于治疗激酶介导的疾病，其中R1、R2、R3、R4、a、b和c在此定义。
• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action
  作者：Edward S. Lazer、Clara K. Miao、Hin-Chor Wong、Ronald Sorcek、Denice M. Spero、Alex Gilman、Kollol Pal、Mark Behnke、Anne G. Graham

  DOI：10.1021/jm00033a008

  日期：1994.4

  phenylalanine with a cyclohexyl group greatly enhance potency. Several ester bioisosteres that retain potency and enantiomeric selectivity are described. Lead optimization culminated in (S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine+ ++ (43b), IC50 0.001 microM. The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.

  描述了一系列抑制白三烯（LT）生物合成的苯并恶唑胺和苯并噻唑胺类似物。最初的铅（S）-N-（苯并噻唑-2-基）苯丙氨酸乙酯（5a）在筛选程序中被发现，该程序可抑制Ca-离子载体-A23187诱导的人多形核白细胞释放LTB4（IC50 0.23 microM ）。通过结构修饰，确定了5-位上的疏水取代基以及苯丙氨酸的苯环被环己基取代极大地增强了效能。描述了几种保留效力和对映异构体选择性的酯类生物甾体。铅优化最终达到（S）-N- [2-环己基-1-（2-吡啶基）乙基] -5-甲基-2-苯并恶唑胺+ ++（43b），IC50 0.001 microM。所述化合物不是5-脂氧合酶的抑制剂，而是
• 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：Athena Neurosciences, Inc.

  公开号：US06291453B1

  公开（公告）日：2001-09-18

  Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及一种能够结合VLA-4的化合物。其中一些化合物还能够抑制白细胞粘附，尤其是由VLA-4介导的白细胞粘附。这些化合物可用于治疗哺乳动物患者（例如人类）的炎症性疾病，如哮喘、阿尔茨海默病、动脉硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可用于治疗多发性硬化等炎症性脑部疾病。
• Organosulfur inhibitors of tyrosine phosphatases
  申请人：Wang Jing

  公开号：US20050065118A1

  公开（公告）日：2005-03-24

  Organosulfur modulators of tyrosine phosphatases and their use in the treatment of disease are disclosed.

  本发明揭示了酚磷酸酶的有机硫调节剂及其在治疗疾病中的应用。

表征谱图